Close menu

SURE

Sunderland Repository records the research produced by the University of Sunderland including practice-based research and theses.

Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors

Borrello, Maria Teresa, Ruzic, Dusan, Paish, Hannah, Graham, Eleanor, Collins, Amy L., Scott, Rebecca, Higginbotham, Sam, Radovic, Branko, Nelson, Glyn, Bulmer, David, Borthwick, Lee A., Robinson, Stuart M., French, Jeremy, Moir, John, White, Steve A., Wilson, Colin, Pandanaboyana, Sanjay, Hammond, John, Thakkar, Rohan, Alrawashdeh, Wasfi, Figueiredo, Rodrigo, Petkovic, Milos, Nikolic, Katarina, Oakley, Fiona, Mann, Derek A. and Mann, Jelena (2025) Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors. The FEBS Journal. ISSN 1742-4658

Item Type: Article

Abstract

Chronic liver injury characterized by unresolved hepatitis leads to fibrosis, potentially progressing to cirrhosis and hepatocellular carcinoma. Effective treatments for halting or reversing liver fibrosis are currently lacking. This study investigates the potential of HDAC6 as a therapeutic target in liver fibrosis. We synthesized two selective HDAC6 inhibitors, DR‐3 and FDR2, and assessed their effects on hepatic stellate cell (HSC) activation and liver fibrosis using human precision cut liver slices (hPCLS). Molecular docking, deacetylation inhibition assays, and various cellular assays were employed to evaluate the specificity and anti‐fibrotic efficacy of these inhibitors. DR‐3 and FDR2 demonstrated high selectivity for HDAC6 over HDAC1, significantly inhibiting HSC activation markers and fibrogenic gene expression. Both inhibitors increased acetylation of α‐tubulin and suppressed TGF‐β1‐induced SMAD signaling in HSCs. In human precision cut liver slices (hPCLS), DR‐3 and FDR2 reduced fibrogenic protein levels and collagen deposition. The selective inhibition of HDAC6 by DR‐3 and FDR2 effectively reduces HSC activation and fibrogenesis in liver models, supporting further investigation of HDAC6 inhibitors as potential anti‐fibrotic therapies.

[img]
Preview
PDF
The FEBS Journal - 2025 - Borrello - Pharmacological manipulation of liver fibrosis progression using novel HDAC6.pdf
Available under License Creative Commons Attribution.

Download (9MB) | Preview

More Information

Uncontrolled Keywords: liver fibrosis, histone deacetylase inhibitors, therapy, human precision cut liver slices, HDAC6 inhibitors
Related URLs:
SWORD Depositor: Publication Router
Depositing User: Publication Router

Identifiers

Item ID: 18879
Identification Number: https://doi.org/10.1111/febs.70062
ISSN: 1742-4658
URI: http://sure.sunderland.ac.uk/id/eprint/18879
Official URL: https://febs.onlinelibrary.wiley.com/doi/10.1111/f...

Users with ORCIDS

ORCID for Maria Teresa Borrello: ORCID iD orcid.org/0000-0003-1365-1358
ORCID for Jelena Mann: ORCID iD orcid.org/0000-0002-7197-5425

Catalogue record

Date Deposited: 28 Mar 2025 12:30
Last Modified: 28 Mar 2025 12:30

Contributors

Author: Maria Teresa Borrello ORCID iD
Author: Jelena Mann ORCID iD
Author: Dusan Ruzic
Author: Hannah Paish
Author: Eleanor Graham
Author: Amy L. Collins
Author: Rebecca Scott
Author: Sam Higginbotham
Author: Branko Radovic
Author: Glyn Nelson
Author: David Bulmer
Author: Lee A. Borthwick
Author: Stuart M. Robinson
Author: Jeremy French
Author: John Moir
Author: Steve A. White
Author: Colin Wilson
Author: Sanjay Pandanaboyana
Author: John Hammond
Author: Rohan Thakkar
Author: Wasfi Alrawashdeh
Author: Rodrigo Figueiredo
Author: Milos Petkovic
Author: Katarina Nikolic
Author: Fiona Oakley
Author: Derek A. Mann

University Divisions

Faculty of Health Sciences and Wellbeing > School of Pharmacy and Pharmaceutical Sciences

Subjects

Sciences > Pharmacy and Pharmacology

Actions (login required)

View Item (Repository Staff Only) View Item (Repository Staff Only)